HK Stock Market Move | ANGELALIGN (06699) rose nearly 9% in intraday trading, with adjusted annual net profit increasing by nearly 63% year-on-year, reaching a total number of cases of over 532,400.
Times Angels (06699) surged nearly 9% this morning, as of the time of writing, it was up 6.24%, at HK$70.7, with a turnover of HK$26.63 million.
This morning, ANGELALIGN (06699) rose by nearly 9% to a high of 70.7 Hong Kong dollars, up 6.24% as of press time, with a turnover of 26.63 million Hong Kong dollars.
In terms of news, ANGELALIGN announced its performance for 2025, with a total of 532,400 cases completed during the year, an increase of 48.1% year-on-year; revenue increased by 37.8% to 370 million US dollars, net profit increased by 163.0% to 26.3 million US dollars, adjusted net profit increased by 62.99% to 43.77 million US dollars; earnings per share were 0.17 US dollars. The company plans to pay a final dividend of 0.48 Hong Kong dollars per share and a special dividend of 4.99 Hong Kong dollars per share. The announcement stated that the improvement in profitability was attributed to increased revenue, leveraging the operational leverage of the Group's global infrastructure, and the timing of the recognition of certain operating and legal expenses during the year.
Related Articles

Guotai Haitong: New demand contributes to the increase in probiotics, optimistic about the new direction of second-generation AKK.

New Stock News | SG Micro Corp (300661.SZ) Hong Kong IPO prospectus invalid

HK Stock Market Move | Some concept stocks of innovative drugs have risen. In the first quarter, the total amount of innovative drugs in China exceeded 60 billion US dollars. The performance of pharmaceutical companies throughout the year is impressive.
Guotai Haitong: New demand contributes to the increase in probiotics, optimistic about the new direction of second-generation AKK.

New Stock News | SG Micro Corp (300661.SZ) Hong Kong IPO prospectus invalid

HK Stock Market Move | Some concept stocks of innovative drugs have risen. In the first quarter, the total amount of innovative drugs in China exceeded 60 billion US dollars. The performance of pharmaceutical companies throughout the year is impressive.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


